二肽基肽酶—4抑制剂联合阿卡波糖对老年2型糖尿病患者血糖控制及体重指数的影响(1)
[摘要]目的 探討二肽基肽酶-4抑制剂联合阿卡波糖治疗老年2型糖尿病(T2DM)的临床效果。方法 选取2015年9月～2017年10月我院收治的108例T2DM患者作为研究对象，按照随机数字表法分为观察组与对照组，每组各54例。在常规饮食、运动干预基础上，对照组给予阿卡波糖治疗，观察组给予阿卡波糖+二肽基肽酶-4抑制剂(西格列汀)治疗，两组均治疗12周。对比两组治疗前后血糖[空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]水平、体质量指数(BMI)及治疗期间的不良反应发生率。结果 治疗后两组患者的FBG、2 h PG、HbA1c水平较治疗前降低(P<0.05)，且观察组低于对照组(P<0.05)；治疗后观察组的BMI较治疗前降低(P<0.05)，对照组较治疗前无明显变化(P>0.05)，且观察组的BMI低于对照组(P<0.05)；治疗期间观察组胃肠胀气、腹泻、鼻咽炎等不良反应发生率与对照组比较，差异无统计学意义(P>0.05)。结论 二肽基肽酶-4抑制剂联合阿卡波糖治疗老年T2DM，有利于患者血糖控制及BMI降低，且具有较高的安全性。
[关键词]2型糖尿病；二肽基肽酶-4抑制剂；阿卡波糖；血糖控制；体重指数
[中图分类号] R587.1 [文献标识码] A [文章编号] 1674-4721(2018)9(b)-0066-03
[Abstract] Objective To investigate the clinical efficacy of dipeptidyl peptidase -4 inhibitors combined with acarbose in the treatment of elderly patients with type 2 diabetes mellitus(T2DM). Methods A total of 108 cases of T2DM patients in our hospital from September 2015 to October 2017 were selected， and divided into the observation group and the control group according to the random number table method， with 54 cases in each group. On the basis of routine diet and exercise intervention， the control group was treated with acarbose， and the observation group was treated with acarbose + dipeptidyl peptidase -4 inhibitors (sitagliptin). Both groups were treated for 12 weeks. The blood glucose level [fasting blood glucose (FBG)， postprandial 2 h blood glucose (2h PG)， glycosylated hemoglobin (HbA1c)]， body mass index (BMI) and incidence of adverse reactions during treatment were compared between the two groups before and after treatment. Results After treatment， the levels of FBG， 2 h PG and HbA1c were lower than those before treatment in two groups (P<0.05)， and the observation group was lower than the control group (P<0.05). After treatment， the BMI in the observation group was lower than that before the treatment (P<0.05)， but there were no significant changes in the control group (P>0.05)， and the BMI in the observation group was lower than that in the control group (P<0.05). There were no significant differences in the incidence of flatulence， diarrhea and nasopharyngitis in the observation group compared with the control group during the treatment (P>0.05). Conclusion Dipeptidyl peptidase -4 inhibitors combined with acarbose in the treatment of elderly T2DM is beneficial to the control of blood sugar and the decrease of BMI， and it has high safety.
[Key words] Type 2 diabetes mellitus； Dipeptidyl peptidase -4 inhibitors； Acarbose； Blood glucose control； Body mass index, 百拇医药(李毅 常海英)
[关键词]2型糖尿病；二肽基肽酶-4抑制剂；阿卡波糖；血糖控制；体重指数
[中图分类号] R587.1 [文献标识码] A [文章编号] 1674-4721(2018)9(b)-0066-03
[Abstract] Objective To investigate the clinical efficacy of dipeptidyl peptidase -4 inhibitors combined with acarbose in the treatment of elderly patients with type 2 diabetes mellitus(T2DM). Methods A total of 108 cases of T2DM patients in our hospital from September 2015 to October 2017 were selected， and divided into the observation group and the control group according to the random number table method， with 54 cases in each group. On the basis of routine diet and exercise intervention， the control group was treated with acarbose， and the observation group was treated with acarbose + dipeptidyl peptidase -4 inhibitors (sitagliptin). Both groups were treated for 12 weeks. The blood glucose level [fasting blood glucose (FBG)， postprandial 2 h blood glucose (2h PG)， glycosylated hemoglobin (HbA1c)]， body mass index (BMI) and incidence of adverse reactions during treatment were compared between the two groups before and after treatment. Results After treatment， the levels of FBG， 2 h PG and HbA1c were lower than those before treatment in two groups (P<0.05)， and the observation group was lower than the control group (P<0.05). After treatment， the BMI in the observation group was lower than that before the treatment (P<0.05)， but there were no significant changes in the control group (P>0.05)， and the BMI in the observation group was lower than that in the control group (P<0.05). There were no significant differences in the incidence of flatulence， diarrhea and nasopharyngitis in the observation group compared with the control group during the treatment (P>0.05). Conclusion Dipeptidyl peptidase -4 inhibitors combined with acarbose in the treatment of elderly T2DM is beneficial to the control of blood sugar and the decrease of BMI， and it has high safety.
[Key words] Type 2 diabetes mellitus； Dipeptidyl peptidase -4 inhibitors； Acarbose； Blood glucose control； Body mass index, 百拇医药(李毅 常海英)